47 related articles for article (PubMed ID: 10803497)
1. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.
Chen H; Xu X; Lin HH; Chen SH; Forsman A; Aasa-Chapman M; Jones IM
J Gen Virol; 2008 Oct; 89(Pt 10):2597-2604. PubMed ID: 18796729
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.
Eda Y; Takizawa M; Murakami T; Maeda H; Kimachi K; Yonemura H; Koyanagi S; Shiosaki K; Higuchi H; Makizumi K; Nakashima T; Osatomi K; Tokiyoshi S; Matsushita S; Yamamoto N; Honda M
J Virol; 2006 Jun; 80(11):5552-62. PubMed ID: 16699036
[TBL] [Abstract][Full Text] [Related]
3. Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies.
Seligman SJ; Binley JM; Gorny MK; Burton DR; Zolla-Pazner S; Sokolowski KA
Mol Immunol; 1996 Jun; 33(9):737-45. PubMed ID: 8811069
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.
Leroux-Roels G; Maes C; Clement F; van Engelenburg F; van den Dobbelsteen M; Adler M; Amacker M; Lopalco L; Bomsel M; Chalifour A; Fleury S
PLoS One; 2013; 8(2):e55438. PubMed ID: 23437055
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development.
Stephenson KE; Neubauer GH; Reimer U; Pawlowski N; Knaute T; Zerweck J; Korber BT; Barouch DH
J Immunol Methods; 2015 Jan; 416():105-23. PubMed ID: 25445329
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
Mascola JR; D'Souza P; Gilbert P; Hahn BH; Haigwood NL; Morris L; Petropoulos CJ; Polonis VR; Sarzotti M; Montefiori DC
J Virol; 2005 Aug; 79(16):10103-7. PubMed ID: 16051803
[No Abstract] [Full Text] [Related]
7. Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein.
Itoh K; Ohshima M; Sonobe M; Saito M; Yoshida A; Hayashi H; Inoue K; Masuko T
Cancer Sci; 2009 Jan; 100(1):126-31. PubMed ID: 19018757
[TBL] [Abstract][Full Text] [Related]
8. A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling.
Imholte GC; Sauteraud R; Korber B; Bailer RT; Turk ET; Shen X; Tomaras GD; Mascola JR; Koup RA; Montefiori DC; Gottardo R
J Immunol Methods; 2013 Sep; 395(1-2):1-13. PubMed ID: 23770318
[TBL] [Abstract][Full Text] [Related]
9. High sensitive detection of carbohydrate binding proteins in an ELISA-solid phase assay based on multivalent glyconanoparticles.
Chiodo F; Marradi M; Tefsen B; Snippe H; van Die I; Penadés S
PLoS One; 2013; 8(8):e73027. PubMed ID: 24014084
[TBL] [Abstract][Full Text] [Related]
10. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.
Robinson JA
J Pept Sci; 2013 Mar; 19(3):127-40. PubMed ID: 23349031
[TBL] [Abstract][Full Text] [Related]
11. Supramolecular Peptide Self-Assemblies Facilitate Oral Immunization.
Curvino EJ; Woodruff ME; Roe EF; Freire Haddad H; Cordero Alvarado P; Collier JH
ACS Biomater Sci Eng; 2024 May; 10(5):3041-3056. PubMed ID: 38623037
[TBL] [Abstract][Full Text] [Related]
12. Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S; Yan C; Millar DG; Yang Q; Heather JM; Langenbucher A; Morton LT; Sepulveda S; Alpert E; Whelton LR; Zarrella DT; Guo M; Minogue E; Lawrence MS; Rueda BR; Spriggs DR; Lu W; Langenau DM; Cobbold M
Cancer Res; 2024 May; 84(9):1534. PubMed ID: 38693893
[No Abstract] [Full Text] [Related]
13. The metabolic changes in rats immunized with BSA conjugate of peptides derived from the N-terminal region of type 4 melanocortin receptor.
Derkach KV; Shpakova EA; Zharova OA; Shpakov AO
Dokl Biochem Biophys; 2014; 458():163-6. PubMed ID: 25366279
[No Abstract] [Full Text] [Related]
14. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
Yu T; Bai Y; Dierich MP; Chen YH
Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
16. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
18. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.
Pinter A
Curr HIV Res; 2007 Nov; 5(6):542-53. PubMed ID: 18045110
[TBL] [Abstract][Full Text] [Related]
19. Back to the future: covalent epitope-based HIV vaccine development.
Paul S; Planque S; Nishiyama Y; Escobar M; Hanson C
Expert Rev Vaccines; 2010 Sep; 9(9):1027-43. PubMed ID: 20822346
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
